These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Immunotherapy of guinea pig cancer with BCG. Zbar B Johns Hopkins Med J Suppl; 1974; 3():121-30. PubMed ID: 4608693 [No Abstract] [Full Text] [Related]
4. Enhancement of carrier-mediated transport after immunologic activation of peritoneal macrophages. Bonventre PF; Straus D; Baughn RE; Imhoff J J Immunol; 1977 May; 118(5):1827-35. PubMed ID: 404359 [TBL] [Abstract][Full Text] [Related]
5. Adjuvants for a tumor-specific vaccine: Bordetella pertussis or mycobacterial cell walls attached to oil droplets. Bartlett GL; Zbar B J Natl Cancer Inst; 1973 May; 50(5):1385-90. PubMed ID: 4351399 [No Abstract] [Full Text] [Related]
6. Immunotherapy of guinea pig cancer with BCG. Zbar B; Rapp HJ Cancer; 1974 Oct; 34(4 Suppl):suppl:1532-40. PubMed ID: 4371315 [No Abstract] [Full Text] [Related]
7. Immunotherapy of guinea pigs with dermal and visceral tumor implants: comparison of living and nonliving BCG. Yarkoni E; Peters L; Rapp HJ; Hanna MG; Hunter JT Infect Immun; 1979 May; 24(2):565-66. PubMed ID: 378859 [TBL] [Abstract][Full Text] [Related]
8. Release of superoxide and hydrogen peroxide from guinea-pig alveolar macrophages during phagocytosis of Mycobacterium bovis BCG. Jackett PS; Andrew PW; Lowrie DB Adv Exp Med Biol; 1982; 155():687-93. PubMed ID: 6297271 [No Abstract] [Full Text] [Related]
9. Plasma-dependent chemotaxis of macrophages toward BCG cell walls and the mycobacterial glycolipid P3. Kelly MT Infect Immun; 1977 Jan; 15(1):180-3. PubMed ID: 319056 [TBL] [Abstract][Full Text] [Related]
10. A comparison of in vitro cell-mediated reactivity against syngeneic tumor cells by various lymphoid cell populations from Bacillus Calmette-Guérin-tumor-cured, tumor-sensitized, tumor-bearing, and normal inbred guinea pigs. Fidler IJ; Kataoka T; Hanna MG Cancer Res; 1976 Dec; 36(12):4459-66. PubMed ID: 187324 [TBL] [Abstract][Full Text] [Related]
11. [Immunity against Mycobacterium, with special reference to the experiments using BCG cell wall]. Yamamoto K Kekkaku; 1976 May; 51(5):155-7. PubMed ID: 819704 [No Abstract] [Full Text] [Related]
12. Microbicidal activity and morphological characteristics of lung macrophages in Mycobacterium bovis BCG cell wall-induced lung granuloma in mice. Kato K; Yamamoto K; Okuyama H; Kimura T Infect Immun; 1984 Aug; 45(2):325-31. PubMed ID: 6086525 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant activity of mycobacterial fractions. I. Purification and in vivo adjuvant activity of cell wall skeletons of Mycobacterium bovis BCG, Nocardia asteroides 131 and Corynebacterium diphtheriae PW8. Azuma I; Kanetsuna F; Taniyama T; Yamamura Y; Hori M Biken J; 1975 Mar; 18(1):1-13. PubMed ID: 807194 [TBL] [Abstract][Full Text] [Related]
15. In vitro immunisation against human tumour cells with bacterial extracts. Sharma B; Tubergen DG; Minden P; Brunda MJ Nature; 1977 Jun; 267(5614):845-7. PubMed ID: 408706 [No Abstract] [Full Text] [Related]
16. Strain differences in lung granuloma formation in response to a BCG cell-wall vaccine in mice. Failure of antigen presentation by low-responder macrophages. Kakinuma M; Onoé K; Yasumizu R; Yamamoto K Immunology; 1983 Nov; 50(3):423-31. PubMed ID: 6354921 [TBL] [Abstract][Full Text] [Related]
17. Tumor suppression by cell walls of mycobacterium bovis attached to oil droplets. Zbar B; Rapp HJ; Ribi EE J Natl Cancer Inst; 1972 Mar; 48(3):831-5. PubMed ID: 4333775 [No Abstract] [Full Text] [Related]
18. Mycobacterial cell wall components in tumor suppression and regression. Ribi EE; Meyer TJ; Azuma I; Zbar B Natl Cancer Inst Monogr; 1973 Dec; 39():115-9. PubMed ID: 4595311 [No Abstract] [Full Text] [Related]